| Project Number | pCODR 10156 |
|---|---|
| Brand Name | Tecentriq |
| Generic Name | Atezolizumab |
| Tumour Type | Lung |
| Indication | Small Cell Lung Cancer (SCLC) |
| Funding Request | In combination with etoposide and a platinum-based chemotherapy for the first line treatment of patients with extensive stage small cell lung cancer (SCLC). Maintenance TECENTRIQ should be continued until loss of clinical benefit or unacceptable toxicity. |
| Review Status | Pending |
| Pre Noc Submission | Yes |
| NOC Date | |
| Manufacturer | Hoffmann-La Roche Limited |
| Submitter | Hoffmann-La Roche Limited |
| Submission Date (Target Date) | March 4, 2019 |
| Submission Type | New Indication |
| Prioritization Requested | |
| Stakeholder Input Deadline (target date based on target submission date) ‡ | March 18, 2019 |
| Check-point meeting (target date) | |
| pERC Meeting (target date) | |
| Initial Recommendation Issued (target date) | |
| Feedback Deadline (target date) ‡ | |
| pERC Reconsideration Meeting (target date) | |
| Final Recommendation Issued (target date) | |
| Notification to Implement Issued |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
